Abcam (ABC) Upgraded at Numis Securities
ABC has been the topic of a number of other reports. JPMorgan Chase & Co. reissued a neutral rating on shares of Abcam in a report on Wednesday, January 2nd. Peel Hunt reissued a hold rating on shares of Abcam in a report on Thursday, December 6th. Finally, Berenberg Bank reissued a buy rating and set a GBX 1,640 ($21.43) target price on shares of Abcam in a report on Tuesday.
Shares of LON:ABC opened at GBX 1,228.19 ($16.05) on Tuesday. Abcam has a 1-year low of GBX 9.73 ($0.13) and a 1-year high of GBX 1,290 ($16.86).
Abcam plc, together with its subsidiaries, produces and distributes research-grade antibodies and associated protein research tools worldwide. The company primarily offers primary and secondary antibodies; ELISA, matched antibody pairs and multiplex immunoassays; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex miRNA assays.
Featured Article: Dividend Aristocrat Index
Receive News & Ratings for Abcam Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam and related companies with MarketBeat.com's FREE daily email newsletter.